Table 2.
X. | Total |
---|---|
(N = 514) | |
Age (years) | |
Median [Min, Max] | 76.0 [51.0, 96.0] |
Sex | |
Male | 385 (74.9%) |
Female | 129 (25.1%) |
Histology | |
Squamous | 57 (11.1%) |
Non-squamous | 457 (88.9%) |
Metastases | |
Yes | 347 (67.5%) |
No | 167 (32.5%) |
Planned use of Trastuzumab | |
Yes | 28 (5.4%) |
No | 486 (94.6%) |
Dose reduction due to renal/hepatic function | |
Yes | 45 (8.8%) |
No | 469 (91.2%) |